Quotes 5-day view Delayed Hong Kong Stock Exchange
4 554 844
5 152 857
3 555 000
4 167 140
4 503 035
Estimated financial data (e) CNY USD
1 051 M
Net income 2022
Net cash position 2022
P/E ratio 2022
2 134 M
Net income 2023
Net Debt 2023
P/E ratio 2023
9 740 M
1 455 M
1 455 M
EV / Sales 2022
EV / Sales 2023
Nbr of Employees
Akeso Inc is an investment holding company mainly engaged in the research and development of biological products. The Company is dedicated to addressing global unmet medical needs in oncology, immunology and other therapeutic areas. The Company's main products include AK104, AK105, AK112 and AK109. The Company conducts its businesses within the China market and to overseas markets.
All news about AKESO, INC.
04/14 Akeso, Inc. Publishes Preclinical Results of PD-1/CD73 Bi-specific Antibody(AK131)at th..
04/14 Akeso, Inc. Announces Publication of Preclinical Results of Its Anti-TIGIT Monoclonal A..
04/05 UBS Adjusts Akeso's Price Target to HK$29.60 From HK$32.40, Keeps at Buy
04/01 Nomura Adjusts Akeso's Price Target to HK$35.81 From HK$53.66, Keeps at Buy
03/30 Akeso, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
03/07 Akeso, Inc. Announces IND Approval from China NMPA for Phase II Clinical Trial of Cadon..
03/07 Akeso Cleared to Start Phase II Study in China of Combination Therapy for Lung Cancer
03/02 Akeso Announces Clinical Trial Collaboration with Chipscreen Biosciences to Evaluate Ca..
03/02 Akeso, Inc. Announces Clinical Trial Collaboration with Chipscreen Biosciences to Evalu..
03/02 Akeso, Chipscreen Bio to Jointly Carry Out Clinical Trials of Combination Therapy for L..
03/02 Akeso announced collaboration with chipscreen biosciences to initiated a clinical trial..
02/10 Akeso, Inc.'s NGF Monoclonal Antibody Approved to Initiate Clinical Trial in Pain (Incl..
02/10 Akeso Cleared to Start Clinical Trial in China of Analgesic for Cancer Pain; Shares Jum..
01/30 Akeso's Ligufalimab and Ivonescimab Obtained Approval to Initiate a Phase II Trial
01/30 Akeso, Inc. Announces First Patient in the Phase III Trial of Ivonescimab Combined with..
News in other languages on AKESO, INC.
Analyst Recommendations on AKESO, INC.
Technical analysis trends AKESO, INC.
Short Term Mid-Term Long Term Trends Bearish Bearish Bearish
Number of Analysts
Last Close Price
Average target price
Spread / Average Target
Yu Xia Chairman, President & Chief Executive Officer
Xiao Jie Xi Chief Financial Officer
Baiyong Li Executive Director, Chief Scientific Officer & SVP
Jun Wen Zeng Independent Non-Executive Director
Yan Xu Independent Non-Executive Director